Loading search results
EXISO
Effekten af Isoflavontilskud og Fysisk træning på Kardiometabolisk Funktion Hos Postmenopausal Kvinder
Sponsor study identifier
interventional
60
1 country
2
Study Start
October 15, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
June 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 1, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this clinical trial is to investigate the role of estrogen and isoflavone supplementation in exercise-induced cellular signaling and cardiometabolic adaptations in premenopausal and postmenopausal women. The study will evaluate vascular function, mitochondrial function, acute and long-term exercise responsiveness, and menopause-related outcomes. The main questions it aims to answer are:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 1, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 24, 2026
Actual (reported)October 16, 2026
Actual (reported)October 15, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 1, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Invasive vascular function
Changes in vascular function assessed by intra-arterial acetylcholine and epoprostanol infusion in the brachial artery via ultrasound doppler. Measured as changes in conductance (ml/min/mmHg)
Change from week 4 (after supplementation) to week 12 (after exercise plus supplementation)
Invasive vascular function
Changes in vascular function assessed by intra-arterial acetylcholine and epoprostanol infusion in the brachial artery via ultrasound doppler. Measured as changes in conductance (ml/min/mmHg)
Change from baseline to week 4 (after supplementation)
Mitochondrial function (skeletal muscle)
Mitochondrial function in skeletal muscle assessed via high resolution respirometry measured in pmol O2/s/mg
Premenopausal women that will undergo 8 weeks of training (3 times per week). Work as a reference group for the study.
Postmenopausal women who was randomly allocated to placebo supplementation. Work as control group in the study. They will receive placebo for 4 weeks, and then continue on placebo+training for 8 weeks.
Participants will consume 120 mL/day of red-clover-derived isoflavone supplement, for 4 weeks prior to and throughout an 8-week supervised exercise training intervention (total duration: 12 weeks).
Participants will complete an 8-week supervised exercise intervention consisting of three 60-minute training sessions per week. The program includes aerobic interval cycling and combined aerobic-resistance circuit training with progressive increases in exercise intensity throughout the intervention period.
Department of Nutrition, Exercise and Sports
Copenhagen, Storkøbenhavn, 2200, Denmark
Faculty of Medical and Health Sciences
Copenhagen, 2200, Denmark
First Submitted
September 24, 2026
First Posted
October 16, 2026
Change from week 4 (after supplementation) to week 12 (after exercise plus supplementation)
Mitochondrial function (skeletal muscle)
Mitochondrial function in skeletal muscle assessed via high resolution respirometry measured in pmol O2/s/mg
Change from baseline to week 4 (after supplementation)
Exercise induced signaling pathways in skeletal muscle (mitochondrial biogenesis and metabolic adaptation) after acute exercise
Molecular pathways in skeletal muscle involved in exercise adaptation after an acute bout of moderate exercise, including pathways related to energy sensing including AMP-activated protein kinase (AMPK), Mitogen-activated protein kinases (MAPK), Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), Mitochondrial transcription factor A (TFAM) and nitric oxide, endothelial nitric oxide synthase (eNOS) signalling measured with transcriptomics, phosphoproteomics, qPCR and western blot. Measurements will be presented as arbitrary units or fold change.
Baseline (pre acute exercise), immediately after acute exercise, and 3 hours after acute exercise (same study day)
Protein signalling in skeletal muscle
Changes in skeletal muscle expression of protein. Western blots will be used to determine endothelial nitric oxide synthase (eNOS), cyclo-oxygenase 1 and 2, prostacyclin synthase, endothelin receptor A and B, VEGF (vascular endothelial growth factor), Thrombospondin-1, Flk-1 (VEGF receptor), Mitochondrial Transcription Factor A (TFAM). All protein content measures will be presented as arbitrary units.
Change from baseline to week 4 (after supplementation) to week 12 (after exercise plus supplementation)
Non-invasive vascular function
Change from week 4 (after supplementation) to week 12 (after exercise plus supplementation)
Non-invasive vascular function
Change from baseline to week 4 (after supplementation)
Mitochondrial function, ROS production in skeletal muscle
Change from week 4 (after supplementation) to week 12 (after exercise plus supplementation)
Mitochondrial function, ROS production in skeletal muscle
Change from baseline to week 4 (after supplementation)
Acute changes in mitochondrial function
Baseline (pre acute exercise), immediately after acute exercise, and 3 hours after acute exercise (same study day)
Body composition
Change from week 4 (after supplementation) to week 12 (after exercise plus supplementation)
Blood pressure
Change from baseline to week 4 (after supplementation) to week 12 (after exercise plus supplementation)
Maximal aerobic capacity
Change from week 4 (after supplementation) to week 12 (after exercise plus supplementation)
Postmenopausal women who was randomly allocated to isoflavone supplementation. They will receive placebo for 4 weeks, and then continue on isoflavone+training for 8 weeks.
Participants will consume 120 mL/day of placebo supplement, for 4 weeks prior to and throughout an 8-week supervised exercise training intervention (total duration: 12 weeks). The placebo beverage is matched in appearance and flavor to the active supplement.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Study Start
October 15, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
June 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 1, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 16, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: